A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models

Basics and Recent Advances in Peptide and Protein Drug Delivery

Benjamin Bruno, Geoffrey D. Miller, Carol S. Lim · Therapeutic Delivery · 2013 · 737 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +14

<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation

Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila et al. · Cancer Discovery · 2012 · 726 citations · Full text

Medicine, Oncology, Pharmacology +17

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

Julien Mazières, Solange Peters, Benoît Lepage et al. · Journal of Clinical Oncology · 2013 · 659 citations

Medicine, Molecular Genetics, Oncology +15

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 627 citations · Full text

Medicine, Oncology, Pharmacology +17

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Shizhen Emily Wang, Archana Narasanna, Marianela Pérez-Torres et al. · Cancer Cell · 2006 · 468 citations · Full text

Medicine, Cancer Biology, Oncology +16